Complete production and quality assurance of the plasmids to be used in the GMP production of CG01.
Cobra Produces Master Cell Banks for CombiGene’s Gene Therapy
Cobra Biologics has successfully produced and supplied two further DNA plasmids for the production of CombiGene AB’s gene therapy drug candidate CG01, which is being developed for the treatment of drug-resistant focal epilepsy. This completes delivery of all plasmids required to progress to the next phase of the project.
Cobra Biologics, part of the Cognate BioServices family, has signed a supply agreement with AstraZeneca UK Ltd. to provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19, Cobra announced in a June 16, 2020 press release. The production agreement is part of AstraZeneca’s program with the University of Oxford to ensure broad and equitable supply of the vaccine throughout the world, at no profit, during the COVID-19 pandemic.
Cobra Biologics, an international CDMO, has successfully produced and delivered the first DNA plasmid required to produce CombiGene’s gene therapy drug candidate CG01, for the treatment of drug-resistant focal epilepsy.
Cognate BioServices closes Series B and completes acquisition of Cobra Biologics
CombiGene AB, a gene therapy company, has signed an agreement with the CDMO Cobra Biologics for the production of drug candidate CG01 for early clinical trials. The agreement with Cobra consists of three separate contracts that will be undertaken, specifically quality, production of plasmids and production of CG01.
Keele and Stirling, UK, 1 February 2018: Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) of biologics and pharmaceuticals, and Symbiosis Pharmaceutical Services (Symbiosis), a contract manufacturing organisation (CMO) specialising in sterile Fill Finish, today announced that they have been awarded a 16-month collaborative grant of £1.9m from Innovate UK.
Cobra Biologics has been awarded £2.6 million ($3.4 million) capital infrastructure investment by Innovate UK.